|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003320,
umls-concept:C0005795,
umls-concept:C0035647,
umls-concept:C0039593,
umls-concept:C0042749,
umls-concept:C0086409,
umls-concept:C0166049,
umls-concept:C0205258,
umls-concept:C0205473,
umls-concept:C0220847,
umls-concept:C0332464,
umls-concept:C0370003,
umls-concept:C1257890,
umls-concept:C1511790,
umls-concept:C1521797,
umls-concept:C1707520,
umls-concept:C2347026,
umls-concept:C2603343,
umls-concept:C2737043
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1997-4-22
|
|
pubmed:abstractText |
The detection of antibody to the second envelope protein (E2) of the hepatitis C virus (HCV) has been hampered by the lack of suitable antigens. A previously described E2 recombinant antigen (CHO-E2) expressed as a non-fused, highly glycosylated protein in mammalian cells was used to detect specific antibody (anti-E2) in samples from blood donors and viraemic patients showing positive or indeterminate results for anti-HCV after a wide serological study. Anti-E2 was detected in 50-75% of the donors positive for anti-HCV, 80% of viraemic immunocompetent patients with anti-NS3 alone and 28% of non-viraemic donors with anticore alone. In donors with anti-NS3 (15 samples) or anti-NS4 (51 samples) alone, anti-E2 was found occasionally (3 cases). Moreover, two anti-E2-positive samples from viraemic patients were misidentified by some commercial assays for screening anti-HCV. These results suggest that testing for anti-E2 may be useful for improving the performance of the current assays for anti-HCV screening and confirmation.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0042-9007
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
70
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
213-6
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9123926-Animals,
pubmed-meshheading:9123926-Antibody Specificity,
pubmed-meshheading:9123926-Blood Donors,
pubmed-meshheading:9123926-CHO Cells,
pubmed-meshheading:9123926-Cricetinae,
pubmed-meshheading:9123926-Hepacivirus,
pubmed-meshheading:9123926-Hepatitis C,
pubmed-meshheading:9123926-Hepatitis C Antibodies,
pubmed-meshheading:9123926-Hepatitis C Antigens,
pubmed-meshheading:9123926-Humans,
pubmed-meshheading:9123926-Immunocompetence,
pubmed-meshheading:9123926-Immunocompromised Host,
pubmed-meshheading:9123926-Mass Screening,
pubmed-meshheading:9123926-Middle Aged,
pubmed-meshheading:9123926-RNA, Viral,
pubmed-meshheading:9123926-Recombinant Proteins,
pubmed-meshheading:9123926-Sensitivity and Specificity,
pubmed-meshheading:9123926-Seroepidemiologic Studies,
pubmed-meshheading:9123926-Viral Envelope Proteins,
pubmed-meshheading:9123926-Viremia
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Detection of antibody to hepatitis C virus E2 recombinant antigen among samples indeterminate for anti-HCV after wide serological testing and correlation with viremia. The Spanish Study Group for Blood Donors at Risk of Transmission of HCV.
|
|
pubmed:affiliation |
Department of Diagnosis, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
